Alzheimer Disease
Conditions
Keywords
Autologous Adipose-derived Stem Cells (AdMSCs)
Brief summary
This is a single patient emergency expanded access clinical study to assess the safety of administering autologous AdMSCs to an incurable Alzheimer disease patient. The study subject will be evaluated for disease-associated severity according to symptoms, cognitive function, memory, and quality of life.
Interventions
Sponsors
Celltex Therapeutics Corporation
Eligibility
Inclusion criteria
* The patient is diagnosed with later stage of Alzheimer Disease with sever cognitive disability. * All current anti-Alzheimer medicines cannot prevent disease progression and the patient's mental and physical ability persistently declined * Patient's legal guardian and caregiver must voluntarily sign an approved written consent form after ample explanation of the proposed therapy.
Exclusion criteria
* Current diagnosis of malignancy * Renal/liver dysfunction: Exceed two times as normal subject * Pregnant or nursing * Received other trial drugs within 30 days after participation of this study * Experienced major surgery or trauma in the last 14 days
Outcome results
None listed